Loading
Life sciences · Journal article
Cureus · October 20, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Metastatic breast cancer (MBC) with a luminal A profile typically follows an indolent clinical course.However, the pleomorphic lobular subtype can manifest aggressive biology with an atypical dissemination pattern and high tumor burden.We report a case of a 42-year-old female diagnosed with de novo luminal A MBC, characterized by an exuberant multimetastatic state involving multiple visceral organs, serosal surfaces, soft tissues, and the axial and appendicular skeleton.Given this high tumor burden, the patient initiated first-line therapy with the CDK4/6 inhibitor ribociclib in combination with letrozole and goserelin.A near-complete metabolic response was observed across all sites monitored by PET/CT after seven months of treatment.This case highlights the clinical efficacy of combining CDK4/6 inhibitors with endocrine therapy even in scenarios of aggressive, high-volume multimetastatic disease.